Onco3R Therapeutics Announces Approval of First Clinical Trial Application for Novel SIK3 inhibitor O3R-5671 in Autoimmune Diseases

globenewswire

Onco3R Therapeutics Announces Approval of First Clinical Trial Application for Novel SIK3 inhibitor O3R-5671 in Autoimmune Diseases – NEWSnet – News… as it used to be

More Press Releases

April 30, 2026

Jet Linx Enhances Maintenance Operations with Veryon Tracking & Defect Analysis

April 30, 2026

Canopy Declares the Era of the Autonomous Firm

April 30, 2026

iCapital®, With Anthropic, to Power AI‑Driven Client Experience for Alternatives, Structured Investments, and Annuities

April 30, 2026

Onco3R Therapeutics Announces Approval of First Clinical Trial Application for Novel SIK3 inhibitor O3R-5671 in Autoimmune Diseases

Jet Linx Enhances Maintenance Operations with Veryon Tracking & Defect Analysis

Canopy Declares the Era of the Autonomous Firm

iCapital®, With Anthropic, to Power AI‑Driven Client Experience for Alternatives, Structured Investments, and Annuities

Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress